2. Disease Areas
  3. Metabolic or Endocrine Disease
  4. Mineral Metabolism
  5. Hyperphosphatemia

Hyperphosphatemia

Hyperphosphatemia is an electrolyte disorder characterized by elevated phosphate levels in the blood, typically defined as serum phosphate exceeding 5 mg/dL (1.6 mmol/L) in adults. It arises from increased phosphate intake, reduced renal excretion, or pathological shifts of intracellular phosphate into the extracellular space. Common causes include chronic kidney disease, especially end-stage renal disease (ESRD), where prevalence ranges from 50% to 74%, and conditions such as hypoparathyroidism, pseudohypoparathyroidism, diabetic ketoacidosis, and certain oncologic treatments like liposomal amphotericin. While many patients are asymptomatic, complications may include soft tissue calcification, joint calcification, and muscle spasms due to secondary hypocalcemia. Genetic mutations in FGF23, GALNT3, or KL can also contribute to the disorder. Management involves dietary phosphate restriction, phosphate-binding medications, and dialysis in severe cases.

Hyperphosphatemia (2):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-145894
    NaPi2b-IN-2 2227445-31-8 99.02%
    NaPi2b-IN-2 is a potent inhibitor of sodium-dependent phosphate transporter 2b (SLC34A2, NaPi2b), with an IC50 value of 38 nM against human NaPi2b. NaPi2b-IN-2 reduces intracellular phosphate levels and enhances innate immune gene expression. NaPi2b-IN-2 can be used in research related to hyperphosphatemia.
    NaPi2b-IN-2
  • HY-159978
    EOS789 1628848-73-6 99.14%
    EOS789 is an orally active sodium-dependent phosphate transporter inhibitor, with IC50 values of 6.8, 1.5, and 1.7 μM against human NaPi-IIb, PiT-1, PiT-2, respectively; and IC50 values of 3.9, 1.9, and 1.7 μM against rat NaPi-IIb, PiT-1, PiT-2, respectively. EOS789 inhibits intestinal phosphate absorption, increases fecal phosphate excretion, reduces urinary phosphate excretion, and decreases the levels of serum phosphate, FGF23, and adult parathyroid hormone. EOS789 ameliorates ectopic thoracic aortic calcification, renal injury and hyperphosphatemia, and inhibits the expression of fibrosis markers. EOS789 can be used for the research of hyperphosphatemia and chronic kidney disease-mineral and bone disorder (CKD-MBD).
    EOS789